Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureBriana A. Santo, A. Karim Ahmed, Samuel Emerson
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The 2021 WHO classification of tumors of the central nervous system: a summary
10.1093/neuonc/noab106 · 2021
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma
10.1126/science.1232245 · 2013
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
10.1038/nm.4293 · 2017
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
10.1007/s00401-012-0998-0 · 2012
H3 K27M-altered glioma and diffuse intrinsic pontine glioma: semi-systematic review of treatment landscape and future directions
10.1093/neuonc/noad220 · 2024
Prognostic indicators for H3K27M-Mutant diffuse midline glioma: a population-based retrospective surveillance, epidemiology, and end results database analysis
10.1016/j.wneu.2023.07.001 · 2023
Epigenetic protein families: a new frontier for drug discovery
10.1038/nrd3674 · 2012
The expanding landscape of ’oncohistone’ mutations in human cancers
10.1038/s41586-019-1038-1 · 2019
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition
10.1073/pnas.1614120113 · 2016
Histone mutations in cancer
10.1042/bst20210567 · 2023
The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas
10.1126/science.aae0065 · 2016
Chromatin structure: a repeating unit of histones and DNA
10.1126/science.184.4139.868 · 1974
Nucleosome structure and function
10.1021/cr500373h · 2015
Crystal structure of the nucleosome core particle at 2.8 A resolution
10.1038/38444 · 1997
Translating the histone code
10.1126/science.1063127 · 2001
Regulation of chromatin by histone modifications
10.1038/cr.2011.22 · 2011
Chromatin modifications and their function
10.1016/j.cell.2007.02.005 · 2007
Histone methylation: a dynamic mark in health, disease and inheritance
10.1038/nrg3173 · 2012
Histone lysine methylation dynamics: establishment, regulation, and biological impact
10.1016/j.molcel.2012.11.006 · 2012
Histone lysine demethylases: emerging roles in development, physiology and disease
10.1038/nrg2218 · 2007
KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease
10.2217/epi.15.9 · 2015
50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond
10.1038/nrm3931 · 2015
Perceiving the epigenetic landscape through histone readers
10.1038/nsmb.2436 · 2012
Readers of histone modifications
10.1038/cr.2011.42 · 2011
Targeting bromodomains: epigenetic readers of lysine acetylation
10.1038/nrd4286 · 2014
The mechanisms behind the therapeutic activity of BET bromodomain inhibition
10.1016/j.molcel.2014.05.016 · 2014
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
10.1038/nature10833 · 2012
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
10.1038/ng.1102 · 2012
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
10.1038/nm.4296 · 2017
Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
10.1126/sciadv.aau5935 · 2018
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas
10.1016/j.ccr.2013.10.006 · 2013
Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas
10.1016/j.ccell.2019.04.004 · 2019
BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma
10.1172/jci174794 · 2024
Systematic review of diffuse hemispheric glioma, H3 G34-mutant: outcomes and associated clinical factors
2022
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon
10.1038/s41698-025-01070-w · 2025
Glioblastoma with primitive neuronal component: an immunohistochemical study and review of literature
10.1016/j.jocn.2021.09.004 · 2021
Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas
10.1007/s00401-013-1095-8 · 2013
Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells
10.1186/s40478-020-01092-4 · 2020
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models
10.1172/jci154229 · 2022
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
10.1038/nrd4360 · 2014
Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas
10.3389/fgene.2021.742561 · doi-reference
Drug delivery strategies for paediatric diffuse midline gliomas
10.1016/j.addr.2025.115695 · doi-reference
Clinical efficacy of ONC201 in H3K27M-Mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
10.1158/2159-8290.cd-23-0131 · doi-reference
Dordaviprone: first approval
10.1007/s40265-025-02252-3 · doi-reference
ONC201 and imipridones: anti-cancer compounds with clinical efficacy
10.1016/j.neo.2020.09.005 · doi-reference
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas
10.1093/neuonc/noac041 · doi-reference
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "window-of-opportunity" study
10.1093/neuonc/noac263 · doi-reference
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
10.1016/j.celrep.2021.108994 · doi-reference
Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma
10.1126/scitranslmed.adr1557 · doi-reference
Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells
10.1038/s41419-020-02800-7 · doi-reference
Epigenetic-targeted treatments for H3K27M-Mutant midline gliomas
10.1007/978-981-15-8104-5_6 · doi-reference
TIP-09. A phase 0/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma participants with MTAP deletion
10.1093/neuonc/noaf201.1669 · doi-reference
PRMT5 maintains tumor stem cells to promote pediatric high-grade glioma tumorigenesis
10.1158/1541-7786.mcr-24-0233 · doi-reference
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo
10.1038/s41598-023-48652-x · doi-reference
Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: updated phase 1b results of symphony-1 with 22.5 months follow-up
10.1182/blood-2023-179910 · doi-reference
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
10.1093/jnci/djad085 · doi-reference
H3K27M mutant glioma: disease definition and biological underpinnings
10.1093/neuonc/noad164 · doi-reference
Histone H3.3K27M represses
10.1158/1541-7786.mcr-16-0389 · doi-reference
The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells
10.1101/gad.415507 · doi-reference
Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation
10.1002/ddr.21796 · doi-reference
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
10.1016/s1470-2045(20)30441-1 · doi-reference
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
10.1016/s1470-2045(20)30451-4 · doi-reference
Tazemetostat: first approval
10.1007/s40265-020-01288-x · doi-reference
Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma
10.1158/1078-0432.ccr-18-3890 · doi-reference
Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
10.1038/nm.3716 · doi-reference
GSK-J4: an H3K27 histone demethylase inhibitor, as a potential anti-cancer agent
10.1002/ijc.34559 · doi-reference
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma
10.3109/10428194.2015.1117611 · doi-reference
Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome
10.1111/bjd.14427 · doi-reference
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors
10.1158/1078-0432.ccr-13-0312 · doi-reference
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models
10.1093/neuonc/noaa249 · doi-reference
Fimepinostat impairs NF-κB and PI3K/AKT signaling and enhances gemcitabine efficacy in H3.3K27M-Diffuse intrinsic pontine glioma
10.1158/0008-5472.can-23-0394 · doi-reference
A phase 1 trial of fimepinostat in children and adolescents with relapsed and refractory solid and CNS tumors
10.1002/cam4.71417 · doi-reference
Dual HDAC and PI3K inhibition abrogates NFκB- and FOXM1-Mediated DNA damage response to radiosensitize pediatric high-grade gliomas
10.1158/0008-5472.can-17-3691 · doi-reference
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling
10.1158/1078-0432.ccr-12-0055 · doi-reference
Phase I study of vorinostat and temsirolimus in newly diagnosed or progressive diffuse intrinsic pontine glioma
10.1002/pbc.31619 · doi-reference
Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas
10.7554/elife.96257.3 · doi-reference
Microtubule-targeting combined with HDAC inhibition is a novel therapeutic strategy for diffuse intrinsic pontine gliomas
10.1158/1535-7163.mct-23-0179 · doi-reference
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a children’s oncology group report
10.1093/neuonc/noab188 · doi-reference
Pediatric phase I trial and pharmacokinetic study of vorinostat: a children’s oncology group phase I consortium report
10.1200/jco.2009.25.9119 · doi-reference
PNOC015: repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma
10.1093/neuonc/noad105 · doi-reference